A best evidence topic was written according to a structured protocol. The question addressed was, should the practising interventional cardiologist use drug-eluting stents (DESs) or bare-metal stents (BMSs) when undertaking primary percutaneous coronary intervention (PCI) in diabetic patients. The relevant outcomes that were used to determine the answer to this question included: in-stent restenosis, target vessel revascularization (TVR), mortality, myocardial infarction and in-stent thrombosis. The OVID Medline database was used to carry out the reported search for abstracts of relevant journal articles. Altogether 102 papers were found, of which 7 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. From the evidence available, we conclude that in-stent restenosis is less likely to occur over a follow-up of at least 6 months if a DES is used instead of a BMS. Furthermore, TVR is less likely to be required in diabetic patients who receive a DES in comparison with a BMS. Nevertheless, no significant difference in mortality between stents was detected by the studies reviewed. This included no difference in the incidence of cardiac and non-cardiac causes of death. There was evidence showing that DESs are associated with a decrease in the risk of myocardial infarction and, in particular, a decrease in non-Q-wave myocardial infarction. However, there was also conflicting evidence demonstrating no significant difference in the incidence of myocardial infarction between diabetic patients who had received a BMS or a DES. Moreover, the available evidence showed no significant difference in the risk of in-stent thrombosis for all DESs with the exception of Sirolimus eluting stents in which the evidence was not consistent. In summary, the available evidence supports the use of DESs over BMSs in diabetic patients undergoing primary PCI.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS [1] .
THREE-PART QUESTION
In [diabetic patients undergoing primary percutaneous coronary intervention] are [drug-eluting stents superior to bare-metal stents] with regard to [restenosis, efficacy and complications]?
CLINICAL SCENARIO
A 55-year old male with known diabetes has been admitted to hospital with an acute ST-elevation myocardial infarction. He is a candidate for primary percutaneous coronary intervention. The on-call registrar suggests that, in light of this gentleman's diabetes, a drug-eluting stent (DES) may provide the most benefit, reducing the risk of in-stent restenosis and target vessel revascularization (TVR). You are called into theatre to assist the on-call consultant who is in the process of deploying a BMS. The consultant states that he uses bare-metal stents regardless of diabetic status; he claims that, in his experience, it improves his patient outcomes. Unclear on the best evidence surrounding the use of BMSs versus DESs in diabetic patients you resolve to check the literature yourself.
SEARCH STRATEGY
The Medline 1985 to February 2013 using the OVID interface was used. [ 
SEARCH OUTCOME
One hundred and two papers were found using the reported search. From these, seven papers were identified that provided the best evidence to answer the question. These are presented in Table 1 .
RESULTS
Patti et al. [2] demonstrated that in 1141diabetic patients who had undergone PCI, in-stent restenosis was less likely to occur over a follow-up period of at least 6 months in patients who received DESs compared with BMSs (8 vs 41%, respectively [odds ratio (OR) = 0.13, 95% confidence interval (CI) 0.09-0.20, P < 0.00001]). Furthermore, Boyden et al. [3] showed that in comparison with BMSs, DESs were associated with an 86% decrease in the risk of in-stent restenosis. (42 vs 5.9% [relative risk (RR) = 0.14, 95% CI 0.10-0.22, P < 0.001]). Additionally, it was shown by Kimura et al. Kumbhani et al. [5] found that diabetic patients who received either a Paclitaxel or Sirolimus ES were less likely to require TVR in a follow-up of at least 6 months (RR = 0.35 [95% CI 0.27-0.46, P < 0.0001]). With regard to patients who received specifically Paclitaxel ESs, Kirtane et al. [6] showed that, over a 4-year followup period, TVR was carried out less frequently than in patients who had received BMSs (12.4 vs 24.7% [P < 0.0001]). Moreover, Stettler et al. [7] found that in follow-up of at least 6 months, Paclitaxel ESs were associated with a decreased rate of TVR (hazard ratio (HR) = 0.38 [95% CI 0.26-0.56]). Additionally, Stettler et al. [7] demonstrated that Serolimus ESs are also less likely than BMSs to require TVR (HR = 0.29 [95% CI 0.19-0.45]).
As a direct corollary, Bangalore et al. [8] carried out a large-scale meta-analysis that included 10 714 diabetic patients, which compared BMSs with different types of DESs. As this is the most recent study, it is likely that these results are the most reliable. Bangalore et al. [8] [7] and Bangalore et al. [8] all showed no significant difference in mortality between DESs and BMSs in diabetic patients.
Patti et al. [2] demonstrated that the incidence of myocardial infarction was significantly decreased in the DES group in comparison with the BMS group (3.5 vs 7.2%, respectively [P = 0.02]). [8] found no significant difference between DESs and BMSs with regard to myocardial infarction. However, Kumbhani et al. [5] showed that there was a significant difference with respect to non-Q-wave myocardial infarction (RR = 0.57 [95% CI 0.32-0.99, P = 0.046]) but not Q-wave myocardial infarction (RR = 0.72 [95% CI 0.25-2.07, P = 0.54]).
Both Patti et al. [2] and Kumbhani et al. [5] demonstrated nonsignificant difference between DESs and BMSs with regard to stent thrombosis (P = 0.98 and 0.12, respectively). Furthermore, in specifically Paclitaxel ESs, Kirtane et al. [6] found no significant difference in stent thrombosis (1.4 vs 1.2% [P = 0.92]). Likewise, Stettler et al. [7] showed a non-significant difference between Paclitaxel ESs and BMSs (HR = 0.73 [95% CI 0.19-2.80]). However, it was shown by Stettler et al. [7] that there is a significant difference in stent thrombosis when comparing Sirolimus ESs against BMSs; Sirolimus ESs were associated with a decrease in stent thrombosis (HR = 0.20 [95% CI 0.05-0.68]). Conversely, Bangalore et al. [8] found that Sirolimus ESs were not superior to BMSs (RR = 0.64 [95% CI 0.36-1.14]). The two confidence intervals do cross over and so it is possible that the true value lies between 0.36 and 0.68; however, the RR and HR may not be comparable. Both are large sample sizes, 3852 vs 10 714.
A total of 73 references were used in the meta-analyses/pooled analyses that had been identified for this BET. Furthermore, 26 (35.6%) were referenced in more than one study. Therefore, there is a degree of duplication in results. Kimura et al. [4] and Kirtane et al. [6] had 0 exclusive references, whereas the meta-analyses published by Stettler et al. [7] and Bangalore et al. [8] had 17 and 21 unique references, respectively. Nevertheless, this does not decrease the validity of the conclusions drawn in this BET.
CLINICAL CONCLUSION
The evidence demonstrates that in-stent restenosis and TVR are less likely to occur in diabetic patients who receive a DES compared with a BMS. Furthermore, the evidence shows that there is no significant difference in mortality between DESs and BMSs. On the other hand, there is conflicting evidence with regard to myocardial infarction and stent thrombosis; nevertheless, the evidence favours a non-significant difference in both outcomes. In summary, DESs are superior to BMSs with regard to clinical outcomes and should be used routinely in diabetic patients undergoing primary PCI.
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